If, as ivonescimab’s victory over Keytruda suggested, PD-(L ... Akeso and Summit are leading the race, but BioNTech is well ...

Results from the study, which focused on gynecological malignant tumors, were presented at the Society for Immunotherapy of ...

Jemperli plus chemotherapy demonstrated superior overall survival compared to Keytruda in advanced NSCLC, with a median OS of ...

BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...

Keytruda is currently indicated in a variety of cancers ... “surpassing traditional checkpoint inhibitors.” Thus far, ...

Aethlon Medical has enrolled the first patient in its Australian clinical trial evaluating the safety, feasibility, and ...

Keytruda in early-stage triple-negative breast cancer led to immune-related adverse effects, including severe GI issues and ...

Aethlon Medical reaches key milestone with enrollment of first patient in its Hemopurifier cancer trial in Australia: San Diego Wednesday, November 13, 2024, 15:30 Hrs [IST] Aethl ...

Vernon Bernardino has given his Buy rating due to a combination of factors, including promising preliminary results from Citius Pharmaceuticals’ ongoing clinical trial of Lymphir in combination with ...

Citius Pharmaceuticals (CTXR) and Citius Oncology (CTOR) announced “promising” preliminary results from an ongoing ...

Rahway: Merck, known as MSD outside of the United States and Canada, and Moderna, Inc., announced the initiation of INTerpath ...

The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...